CytomX Therapeutics Inc (NASDAQ:CTMX) hit a new 52-week high during trading on Monday . The stock traded as high as $29.42 and last traded at $29.22, with a volume of 219100 shares trading hands. The stock had previously closed at $29.22.
CTMX has been the subject of several analyst reports. BidaskClub downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Zacks Investment Research downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 19th. ValuEngine downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Citigroup began coverage on CytomX Therapeutics in a report on Friday, January 5th. They set a “buy” rating and a $40.00 target price for the company. Three analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. CytomX Therapeutics currently has a consensus rating of “Buy” and an average target price of $32.78.
In other CytomX Therapeutics news, Director Frederick W. Gluck sold 5,000 shares of the company’s stock in a transaction dated Tuesday, December 26th. The stock was sold at an average price of $22.29, for a total value of $111,450.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Debanjan Ray sold 2,548 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $26.69, for a total value of $68,006.12. Following the completion of the transaction, the chief financial officer now directly owns 4,741 shares in the company, valued at $126,537.29. The disclosure for this sale can be found here. Insiders have sold 56,466 shares of company stock worth $1,267,014 over the last three months. 8.00% of the stock is owned by insiders.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.